Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimer's Vaccine
Source: Streetwise Reports  (9/30/21)
Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002, a cell-based therapeutic vaccine designed to restore patients' immunological systems, providing them with the ability to combat Alzheimer's Disease. The FDA has granted the firm approval to initiate a combined Phase 1/2 clinical trial in Q1/22.

More >

COVID-19 Vaccine Could Be Approved in Q4/21 for 5 to 11 Year Olds
Source: Streetwise Reports  (9/30/21)
"Label extension for BioNTech and Pfizer's Comirnaty [vaccine] to include use in these younger individuals ought to buoy revenue growth near term," noted an H.C. Wainwright & Co. report. More >

Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough
Source: Streetwise Reports  (9/29/21)
Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial. More >

Cannabis Firm Expands Footprint in Central California With New Distribution Center
Source: Streetwise Reports  (9/28/21)
"The expansion is expected to drive topline sales with greater efficiency," noted a Noble Capital Markets report. More >

Telemedicine Tech Firm Poised to Generate $11 Million of Revenue
Source: Streetwise Reports  (9/24/21)
Reliq Health Technologies signs contracts with three new clients for its proprietary remote healthcare delivery and care tracking platform, which has particularly significant implications during the era of the COVID-19 pandemic. More >

Nanotech Co.'s Shares Trade Higher After Developing Antimicrobial Coating for PPE
Source: Streetwise Reports  (9/23/21)
ZEN Graphene Solutions Ltd. shares traded 13.5% higher after the company reported it delivered its first revenue-generating shipment of ZENGuard, a patent-pending coating with 99% antimicrobial activity. The first commercial shipment follows the firm's announcement yesterday that Health Canada determined ZENGuard enhanced surgical masks are safe for use by Canadians. More >

Dynavax Shares Shoot Up 30% After Its Partner Clover Biopharma Met All Key Efficacy Endpoints in Ph. 2/3 COVID-19 Vaccine Trial
Source: Streetwise Reports  (9/22/21)
Shares of Dynavax Technologies Corp. established a new 52-week high after the company reported that in the global Phase 2/3 SPECTRA COVID-19 vaccine study its collaborative partner Clover Biopharmaceuticals met all primary and secondary efficacy endpoints. Clover's vaccine, which was developed using Dynavax's CpG 1018 adjuvant, demonstrated 100% efficacy against severe COVID-19 and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2, including the Delta, Gamma, and Mu variants. More >

'Poised for Two Key Readouts in Q1/22' as Biopharma Advances Pipeline
Source: Streetwise Reports  (9/21/21)
Rezolute's two drug candidates, one for congenital hyperinsulinism and the other for diabetic macular edema, are discussed in an H.C. Wainwright & Co. report. More >

Inotiv Makes $545 Million Bid for Envigo RMS Holdings to Fortify Research and Drug Discovery Platforms
Source: Streetwise Reports  (9/21/21)
Shares of Inotiv Inc. traded 27% higher to a new 52-week high after the company reported it entered into agreement to acquire Envigo RMS Holding Corp. in a cash and stock deal valued at $545 million which will serve to create a one-stop-shop, discovery-to-approval solution for drug developers. More >

Target Price Raised on Biopharma After It Acquires Company, Splits Stock
Source: Streetwise Reports  (9/20/21)
AzurRx BioPharma now has five additional shots on goal "with the imminent full acquisition of just one compound," a ROTH Capital Partners report noted. More >

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study
Source: Streetwise Reports  (9/20/21)
Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients. More >

Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference
Source: Streetwise Reports  (9/18/21)
Innate Pharma S.A. shares traded 38% higher after the company reported its development partner AstraZeneca Plc. reported positive interim results from its Phase 2 COAST Study to the European Society for Medical Oncology Congress. When taken together with durvalumab, monalizumab was shown to improve progression-free survival and objective response rates in patients with unresectable, Stage III non-small cell lung cancer. More >

Leap Therapeutics Shares Skip Higher on Positive Preliminary Data From Gastric Cancer Study
Source: Streetwise Reports  (9/16/21)
Shares of Leap Therapeutics Inc. traded 38% higher after the company reported positive preliminary data from the Phase 2a DisTinGuish Study of DKN-01 plus tislelizumab at the European Society for Medical Oncology Congress. More >

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients
Source: Streetwise Reports  (9/15/21)
ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed with nonalcoholic steatohepatitis. ROTH rates Inventiva a "Buy" with a 12-month price target of €55/share which represents a nearly four-fold increase over the current share price. More >

Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study
Source: Streetwise Reports  (9/15/21)
Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients. More >

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies
Source: Streetwise Reports  (9/14/21)
H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share. More >

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial
Source: Streetwise Reports  (9/13/21)
Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients. More >

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business
Source: Streetwise Reports  (9/8/21)
Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash. Sanofi aims to strengthen its transplant business with the addition of Kadmon's Rezurockâ„¢ (belumosudil), an FDA-approved, first-in-class treatment for patients 12 years and older with chronic graft-versus-host disease. More >

Medical Device Company's Improved Fundamentals Offer Multiple Expansion Potential
Source: Streetwise Reports  (9/7/21)
ROTH Capital Partners LLC commented in a research report that it is maintaining its "Buy" rating and raising its FY/22 revenue estimates for Dynatronics Corp. to $41 million after the firm pre-announced Q4/21 revenue figures that exceeded prior estimates. More >

Adaptimmune Partners With Genentech to Develop & Market Cancer-Targeted Allogeneic T-Cell Therapies
Source: Streetwise Reports  (9/7/21)
Adaptimmune Therapeutics Plc. shares traded 33% higher after the firm reported it formed a strategic partnership with Genentech to develop several "off-the-shelf" and advanced personalized cancer-targeting allogeneic T-cell therapies. More >

Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD Tech
Source: Streetwise Reports  (9/4/21)
Shares of Impel NeuroPharma Inc. traded to a new 52-week high after the company reported that the U.S. Food and Drug Administration has approved TRUDHESAâ„¢ (dihydroergotamine mesylate), a patient friendly nasal spray that delivers rapid relief and treatment for acute migraine. More >

Reliq Health Technologies Rides Telehealth Reimbursement Wave
Source: Streetwise Reports  (9/2/21)
Global telemedicine company will turn a profit in the current quarter and experience rapid growth after new contracts to provide chronic care management and medicare and medicaid reimbursements expand. More >

Biopharma's Antibody Approved as Hodgkin's Lymphoma Treatment in China
Source: Streetwise Reports  (8/31/21)
"This marks the first regulatory approval of an OmniAb antibody discovery engine-derived antibody since Ligand Pharmaceuticals first acquired the technology in 2016," noted an H.C. Wainwright & Co. report. More >

AC Immune Shares Rise 16% After Phase 2 Alzheimer's Trial Data Shows Significant Reductions in Cognitive Decline
Source: Streetwise Reports  (8/31/21)
AC Immune SA shares set a new 52-week intraday high after the company reported positive cognitive results for tau-targeting monoclonal antibody semorinemab in a clinical study of patients with mild-to-moderate Alzheimer's disease. More >

Israeli Biopharma Advances Five Drug Candidate Trials in Q2/21
Source: Streetwise Reports  (8/30/21)
The progress Can-Fite BioPharma made with these studies is briefly summarized in a Dawson James Securities report. More >